About REXAHN

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.


News

Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update


Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 — A Cancer Cell Specific Anticancer Agent


More


Portfolio